Altimmune (NASDAQ:ALT) Director John Gill Buys 12,500 Shares

Altimmune, Inc. (NASDAQ:ALT) Director John Gill purchased 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was bought at an average cost of $4.10 per share, with a total value of $51,250.00. Following the purchase, the director owned 12,500 shares of the company’s stock, valued at $51,250. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Altimmune Price Performance

Altimmune stock traded down $0.14 during trading hours on Tuesday, reaching $4.00. 4,427,418 shares of the stock were exchanged, compared to its average volume of 3,600,925. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. Altimmune, Inc. has a twelve month low of $2.90 and a twelve month high of $8.05. The company has a market cap of $417.36 million, a P/E ratio of -3.74 and a beta of -0.03. The stock has a 50 day moving average of $4.52 and a two-hundred day moving average of $4.39.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. Equities analysts expect that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Citizens Jmp dropped their price objective on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.83.

Institutional Trading of Altimmune

A number of hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP grew its holdings in shares of Altimmune by 356.6% during the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after purchasing an additional 1,559,562 shares during the last quarter. Vanguard Group Inc. boosted its position in Altimmune by 23.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after buying an additional 1,206,514 shares during the period. Federated Hermes Inc. grew its holdings in Altimmune by 387.7% during the 2nd quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock worth $3,543,000 after acquiring an additional 727,731 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Altimmune during the 3rd quarter worth approximately $2,204,000. Finally, Bank of America Corp DE increased its position in Altimmune by 155.2% in the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock valued at $2,771,000 after acquiring an additional 435,467 shares during the period. 78.05% of the stock is owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.